Oyster Point Pharma Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.74
Dividend & YieldN/A$ (N/A)
Beta 1.19
Market capitalization 300.66M
Operating cash flow -166M
ESG Scores unknown

Company description

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio7.26
Working Capital-0.54
Return On Equity-1.01
Debt To Equity0.9
Fixed Asset Ratio0.22
Fixed Interest Cover-25.89

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 44k 38k 1.77M 3.87M
Total Cashflows From Investing Activities -200k -200k -700k -1.49M
Net Borrowings 95M 95M 95M 95M
Total Cash From Financing Activities 174.99M 174.99M 112.55M 91.64M
Change To Operating Activities -778k 1.41M 2.91M 6.72M
Issuance Of Stock 82.13M 82.13M 112.91M 1.59M
Net Income -16.5M -45.71M -70.52M -100.66M
Change In Cash -17.08M 133.97M 53.45M 787k
Effect Of Exchange Rate
Total Cash From Operating Activities -17.08M -40.81M -58.4M -89.37M
Depreciation 19k 19k 77k 141k
Change To Account Receivables -6.66M -6.66M -6.66M -6.66M
Other Cashflows From Financing Activities -361k -361k -361k -4.95M
Change To Netincome 154k 3.43M 7.36M 12.8M
Capital Expenditures -200k -200k -700k -1.49M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 13.76M 33.63M 39.81M 24.23M
Income Before Tax -16.5M -45.71M -70.52M -100.66M
Net Income -16.5M -45.71M -70.52M -100.66M
Selling General Administrative 2.98M 13.67M 31.18M 95.44M
Gross Profit 23.01M
Ebit -16.74M -47.3M -70.99M -96.66M
Operating Income -16.74M -47.3M -70.99M -96.66M
Interest Expense -3.73M -3.73M -3.73M -3.73M
Income Tax Expense
Total Revenue 24.54M
Cost Of Revenue 1.52M
Total Other Income ExpenseNet 233k 1.59M 469k -4M
Net Income From Continuing Ops -16.5M -45.71M -70.52M -100.66M
Net Income Applicable To Common Shares -16.5M -45.71M -70.52M -100.66M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 946k 5.91M 11.25M 123.08M
Total Stockholder Equity -38.24M 137.3M 186.66M 99.54M
Other Current Liabilities 4.84M
Total Assets 5.7M 143.21M 197.91M 222.62M
Common Stock 1k 21k 26k 27k
Other Current Assets 61k
Retained Earnings -38.52M -84.23M -154.75M -255.41M
Treasury Stock
Cash 5.23M 139.15M 192.59M 193.37M
Total Current Liabilities 940k 5.4M 10.98M 28.8M
Other Stockholder Equity
Property, Plant, and Equipment 66k 978k 1.48M 5.4M
Total Current Assets 5.62M 142.18M 196.37M 215.25M
Net Tangible Assets -38.24M 137.3M 186.66M 99.54M
Net Receivables 6.66M
Accounts Payable 462k 507k 2.28M 6.5M


Insider Transactions

Here are the insider transactions of stock shares related to Oyster Point Pharma Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
ATIEH MICHAEL GStock Award(Grant) at price 0.00 per share.D2022-06-06Director3.57k
SANTEL DONALD JStock Award(Grant) at price 0.00 per share.D2022-06-06Director3.57k
WEISNER AIMEE SStock Award(Grant) at price 0.00 per share.D2022-06-06Director3.57k
BEHBAHANI ALIStock Award(Grant) at price 0.00 per share.D2022-06-06Director3.57k
MURRAY MARK ANTHONYStock Award(Grant) at price 0.00 per share.D2022-06-06Director3.57k
OZAWA CLAREStock Award(Grant) at price 0.00 per share.D2022-06-06Director3.57k
TSAI BENJAMINStock Award(Grant) at price 0.00 per share.D2022-06-06Director3.57k
ELIADES GEORGE CHRISTOPHERStock Award(Grant) at price 0.00 per share.D2022-06-06Director3.57k
SNISARENKO JOHNStock Award(Grant) at price 0.00 per share.D2022-01-07Officer12.1k
LOCHNER DANIEL J.Stock Award(Grant) at price 0.00 per share.D2022-01-07Chief Financial Officer19.5k
NAU JEFFREYStock Award(Grant) at price 0.00 per share.D2022-01-07Chief Executive Officer46.7k
LOCHNER DANIEL J.Conversion of Exercise of derivative security at price 11.51 per share.D2021-11-01Chief Financial Officer8.59k
NAU JEFFREYConversion of Exercise of derivative security at price 1.02 per share.D2021-10-21Chief Executive Officer50k
LINK WILLIAM JSale at price 14.63 - 15.09 per share.I2021-10-18Director550k
VERSANT VENTURE CAPITAL VI, L.P.Sale at price 14.63 - 15.09 per share.I2021-10-18Beneficial Owner of more than 10% of a Class of Security550k
OZAWA CLARESale at price 14.63 - 15.09 per share.I2021-10-18Director and Beneficial Owner of more than 10% of a Class of Security550k
LOCHNER DANIEL J.Conversion of Exercise of derivative security at price 11.51 per share.D2021-09-02Chief Financial Officer7.5k
NAU JEFFREYConversion of Exercise of derivative security at price 1.02 per share.D2021-09-01Chief Executive Officer10k
SANTEL DONALD JStock Award(Grant) at price 0.00 per share.D2021-07-30Director10.11k
LOCHNER DANIEL J.Conversion of Exercise of derivative security at price 11.51 per share.D2021-07-28Chief Financial Officer7.5k
ATIEH MICHAEL GStock Award(Grant) at price 0.00 per share.D2021-06-07Director3.47k
WEISNER AIMEE SStock Award(Grant) at price 0.00 per share.D2021-06-07Director3.47k
BEHBAHANI ALIStock Award(Grant) at price 0.00 per share.D2021-06-07Director3.47k
LINK WILLIAM JStock Award(Grant) at price 0.00 per share.D2021-06-07Director3.47k
MURRAY MARK ANTHONYStock Award(Grant) at price 0.00 per share.D2021-06-07Director3.47k
OZAWA CLAREStock Award(Grant) at price 0.00 per share.D2021-06-07Director3.47k
TSAI BENJAMINStock Award(Grant) at price 0.00 per share.D2021-06-07Director3.47k
ELIADES GEORGE CHRISTOPHERStock Award(Grant) at price 0.00 per share.D2021-06-07Director3.47k
NAU JEFFREYConversion of Exercise of derivative security at price 1.02 per share.D2021-04-02Chief Executive Officer10k
ELIADES GEORGE CHRISTOPHERStock Award(Grant) at price 0.00 per share.D2021-04-02Director21.59k
LOCHNER DANIEL J.Conversion of Exercise of derivative security at price 11.51 per share.D2021-02-24Chief Financial Officer9.11k
NAU JEFFREYConversion of Exercise of derivative security at price 1.02 per share.D2021-02-19Chief Executive Officer10k
SNISARENKO JOHNStock Award(Grant) at price 0.00 per share.D2021-01-29Officer11.22k
LOCHNER DANIEL J.Stock Award(Grant) at price 0.00 per share.D2021-01-29Chief Financial Officer11.22k
NAU JEFFREYStock Award(Grant) at price 0.00 per share.D2021-01-29Chief Executive Officer25.9k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Oyster Point Pharma Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Oyster Point Pharma Inc

Here is the result of two systematic investment strategies applied to Oyster Point Pharma Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Oyster Point Pharma Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Oyster Point Pharma Inc:

Oyster Point Pharma Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -37.23% on the backtest period.

Performance at glance

Performance

-37.23 %

Latent gain

-372.08 $

Invested capital

999.38 $

Annualized return

-18.61 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Oyster Point Pharma Inc

This is the result of two momentum investment strategies applied to Oyster Point Pharma Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Oyster Point Pharma Inc

The following chart shows all the entries opened by the momentum investment system on Oyster Point Pharma Inc:

Oyster Point Pharma Inc momentum entries
  • The first momentum investment strategy would give -45.43% of return on Oyster Point Pharma Inc. That represents -1474.78$ of latent gain with 3245.98$ of employed capital.
  • The second momentum investment strategy would give -41.26% of return on Oyster Point Pharma Inc. That represents -915.79$ of latent gain with 2219.59$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-45.43 %

Latent gain

-1474.78 $

Invested capital

3245.98 $

Annualized return

0 %
Performance at glance (2Q Momentum)

Performance

-41.26 %

Latent gain

-915.79 $

Invested capital

2219.59 $

Annualized return

-27.14 %

Momentum equity curve on Oyster Point Pharma Inc

The following chart shows the equity curve of the two momentum strategies applied to Oyster Point Pharma Inc:

Oyster Point Pharma Inc momentum equity

Note: the dividends potentially given by Oyster Point Pharma Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Oyster Point Pharma Inc

The following chart shows the employed capital evolution of the two momentum strategies on Oyster Point Pharma Inc since the beginning:

Oyster Point Pharma Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Oyster Point Pharma Inc

Buy the dip entry openings on Oyster Point Pharma Inc

Oyster Point Pharma Inc

The performance achieved by the robo-advisor on Oyster Point Pharma Inc is 0%. That represents 0$ of latent gain with 0$ of employed capital. The following chart shows Oyster Point Pharma Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Oyster Point Pharma Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0 $

Invested capital

0 $

Annualized return

0 %

Equity curve of the strategy applied to Oyster Point Pharma Inc

The following chart shows the result of the investment strategy applied to Oyster Point Pharma Inc:

Oyster Point Pharma Inc

Note: the dividends potentially given by Oyster Point Pharma Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Oyster Point Pharma Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Oyster Point Pharma Inc:

Oyster Point Pharma Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Oyster Point Pharma Inc

In this section, I will compare the three previous investment strategies applied to Oyster Point Pharma Inc.

Equity curve comparison on Oyster Point Pharma Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Oyster Point Pharma Inc investment strategy comparison

Employed capital comparison on Oyster Point Pharma Inc

Oyster Point Pharma Inc investment comparison

Performance comparison on Oyster Point Pharma Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -37.23% -372.08$ 999.38$ -18.61%
Momentum 1 quarter -45.43% -1474.78$ 3245.98$ -25.81%
Momentum 2 quarters -41.26% -915.79$ 2219.59$ -27.14%
Non-directional 0% 0$ 0$ 0%
Annualized return comparison

Automatic investment

-18.61 %

Momentum 1Q

-27.14 %

Momentum 2Q

-27.14 %

Non-directional

0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Oyster Point Pharma Inc:

Note: The algorithm computes the probability of correlation between Oyster Point Pharma Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Oyster Point Pharma Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name Oyster Point Pharma Inc
Country United States
City Princeton
Address 202 Carnegie Center
Phone 609 382 9032
Website www.oysterpointrx.com
FullTime employees 303
Industry Biotechnology
Sector Healthcare
Exchange XNAS
Ticker OYST
Market www.nasdaq.com

Oyster Point Pharma Inc ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown